Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns up above $1.08
Key levels
Resistance$0.86
Resistance$0.77
Latest news & SEC filings
ProductMetagenomi Therapeutics wins FDA nod for MGX-001 study and posts Q3 2026 results
ProductMetagenomi Therapeutics wins FDA clearance for MGX-001 hemophilia A study
ProductFDA allows Metagenomi to begin human testing of hemophilia A gene therapy MGX-001
SEC FilingMetagenomi Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All MGX news →Metagenomi Therapeutics is a preclinical biotechnology company creating in vivo genome editing treatments for inherited conditions. Its main wholly owned candidate, MGX-001, aims to treat hemophilia A by inserting a Factor VIII gene at a specific genomic site, and the company is exploring additional protein-deficiency disorders plus partnered cardiometabolic programs. It discovers and engineers gene editing tools such as nucleases, base editors, and integration systems using metagenomics. The company is based in the United States and works with collaborators including Ionis.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MGX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$7.64
10
Moat Score
NONE
1/9
Piotroski Score
-2.3
Altman Z-Score
Insider Signal
SELLING
2 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Reid Laurence | director | Buy | 19,883 | $23K | Sep 9, 2026 |
| Reid Laurence | director | Buy | 117 | $138.06 | Sep 9, 2026 |
| Wapnick Pamela | officer | Sale | 2,884 | $4K | Jun 5, 2026 |
| Irish Jian | director officer | Sale | 3,737 | $5K | Jun 5, 2026 |
| Wein Matthew | officer | Sale | 558 | $724.84 | Jun 5, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-51.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
0%
FCF Growth YoY
20.3%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for MGX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:40:24 | $0.74 | 1,189 | $$880 | SELL |
| 21:26:57 | $0.76 | 3,474 | $$3K | SELL |
| 20:51:50 | $0.78 | 1,100 | $$856 | SELL |
| 20:50:34 | $0.78 | 2,300 | $$2K | SELL |
| 20:47:43 | $0.79 | 2,600 | $$2K | BUY |
5 dark pool trades shown · $$8K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Metagenomi Therapeutics, Inc. (MGX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Metagenomi Therapeutics, Inc. (MGX) is at $0.76, up 8.04% (+$0.06) at the Nov 11, 2026 close.
Latest MGX news — Nov 11, 2026: Metagenomi Therapeutics wins FDA nod for MGX-001 study and posts Q3 2026 results · Nov 10, 2026: Metagenomi Therapeutics wins FDA clearance for MGX-001 hemophilia A study
Analyst ratings for MGX: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
MGX last reported on Aug 10, 2026: EPS -$0.73 vs -$0.55 expected — a miss of 32.0%.
MGX does not currently pay a dividend.
Resistance: $0.77, $0.86, $1.08.
Insider activity: SELLING, 2 buys and 6 sells in the last 90 days.
Nov 11, 2026: Metagenomi Therapeutics wins FDA nod for MGX-001 study and posts Q3 2026 results · Nov 10, 2026: Metagenomi Therapeutics wins FDA clearance for MGX-001 hemophilia A study · Nov 10, 2026: FDA allows Metagenomi to begin human testing of hemophilia A gene therapy MGX-001